Endoscopy as final arbiter in controlled clinical trials in peptic disorders

Area of Science:

• Gastroenterology
• Clinical Trial Design
• Peptic Disorders Research

Background:

• Current clinical trials for peptic disorders heavily rely on endoscopic assessments for 'healing' and 'relapse'.
• These endoscopic endpoints, while objective, may not fully capture the clinical significance of treatment outcomes.
• There is a need to re-evaluate the primary outcome measures in peptic disorder research.

Purpose of the Study:

• To advocate for a broader interpretation of clinical trial outcomes beyond sole reliance on endoscopic findings.
• To highlight the clinical importance of symptom response and side-effect data in peptic disorder trials.
• To address the limitations in the definition and reporting of endoscopic endpoints in recent studies.

Main Methods:

• Review of methodologies and outcome reporting in recent controlled clinical trials for peptic disorders.
• Comparative analysis of endoscopic data versus patient-reported outcomes (symptoms, side effects).
• Critical evaluation of the definitions and reporting standards for endoscopic 'healing' and 'relapse'.

Main Results:

• Endoscopic 'healing' and 'relapse' data, while quantifiable, may be less clinically meaningful than symptom response and side-effect profiles.
• Many recent trials exhibit poorly defined criteria for endoscopic 'healing' and 'relapse'.
• Crucial information regarding residual mucosal lesions post-healing is frequently omitted, limiting a comprehensive assessment.

Conclusions:

• Endoscopy should not serve as the exclusive criterion for evaluating treatment efficacy in peptic disorder clinical trials.
• Symptom response and side-effect data provide clinically relevant insights that warrant greater consideration.
• Improved standardization and reporting of endoscopic findings, including residual lesions, are necessary for robust trial interpretation.